J
Jacob M. Rowe
Researcher at Shaare Zedek Medical Center
Publications - 218
Citations - 12420
Jacob M. Rowe is an academic researcher from Shaare Zedek Medical Center. The author has contributed to research in topics: Leukemia & Transplantation. The author has an hindex of 49, co-authored 218 publications receiving 11147 citations. Previous affiliations of Jacob M. Rowe include Medical College of Wisconsin & Eastern Cooperative Oncology Group.
Papers
More filters
Journal ArticleDOI
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
Marilyn L. Slovak,Kenneth J. Kopecky,Peter A. Cassileth,David H. Harrington,Karl S. Theil,Anwar Mohamed,Elizabeth Paietta,Cheryl L. Willman,David R. Head,Jacob M. Rowe,Stephen J. Forman,Frederick R. Appelbaum +11 more
TL;DR: Cytogenetic risk status is a significant factor in predicting response of AML patients to therapy; however, to tighten treatment correlates within genetically defined AML subsets, a significantly larger leukemia cytogenetic database is warranted.
Journal ArticleDOI
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
Martin S. Tallman,Janet Andersen,Charles A. Schiffer,Frederick R. Appelbaum,James H. Feusner,Angela Ogden,Lois E. Shepherd,Cheryl L. Willman,Clara D. Bloomfield,Jacob M. Rowe,Peter H. Wiernik +10 more
TL;DR: All-trans-retinoic acid as induction or maintenance treatment improves disease-free and overall survival as compared with chemotherapy alone and should be included in the treatment of acute promyelocytic leukemia.
Journal ArticleDOI
Drug therapy for acute myeloid leukemia.
Martin S. Tallman,Martin S. Tallman,Martin S. Tallman,D. Gary Gilliland,D. Gary Gilliland,D. Gary Gilliland,Jacob M. Rowe,Jacob M. Rowe,Jacob M. Rowe +8 more
TL;DR: In insights into the molecular pathogenesis of AML have led to the development of more specific targeted agents and have ushered in an exciting new era of antileukemia therapy.
Journal ArticleDOI
Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission
Peter A. Cassileth,David P. Harrington,Frederick R. Appelbaum,Hillard M. Lazarus,Jacob M. Rowe,Elisabeth Paietta,Cheryl L. Willman,David D. Hurd,John M. Bennett,Karl G. Blume,David R. Head,Peter H. Wiernik +11 more
TL;DR: A postinduction course of high-dose cytarabine can provide equivalent disease-free survival and somewhat better overall survival than autologous marrow transplantation in adults with acute myeloid leukemia.
Journal ArticleDOI
A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).
Jacob M. Rowe,JW Andersen,JJ Mazza,John M. Bennett,E. Paietta,FA Hayes,D Oette,PA Cassileth,Edward A. Stadtmauer,PH Wiernik +9 more
TL;DR: It appears that GM-CSF is safe and efficacious for adult patients greater than 55 to 70 years of age with AML; its major impact is in reducing the duration of neutropenia and therapy-related mortality and morbidity.